Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion
Status:
Not yet recruiting
Trial end date:
2029-09-01
Target enrollment:
Participant gender:
Summary
Since the discovery that Treg suppress anti-tumor immune responses, inhibiting their function
has become a major challenge for the development of efficient immunotherapy for cancer. In
humans, we previously reported the positive results of a first clinical trial using Treg
depletion for anti-tumor response amplification in the field of allogeneic hematopoietic stem
cell transplantation (HSCT). The present project aims at developing this anti-tumor
immunotherapeutic strategy in the same setting, i.e. donor lymphocyte infusion (DLI) for
relapsing hematological malignancies after HSCT, using a new selection marker: CD127. The
choice of this new strategy is supported by our results of a retrospective clinical study and
pre-clinical data. Using human cells, this studies demonstrated, in vitro and in vivo in
animal murine models, that Treg depletion through CD127 positive selection is much more
efficient to improve allogeneic immune responses of donor T-cells as compared to the previous
strategy using the CD25 marker.